Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Transcript
Where are there opportunities to address disparities and improve health equity in the treatment of AML and other hematologic cancers?
I think being able to focus efforts and research on treating underserved patients with these very difficult and challenging diseases is going to be critical to the success of our overall mission to improve outcomes in leukemia patients.
Certainly, we need to do a better job at offering clinical trials to underserved patients who often are underrepresented—or I should say close to always underrepresented—in most large clinical trials. And that deprives those patients of the opportunity to receive potential cutting-edge therapy before it's officially approved, but also denies us, the medical academic community, the opportunity to understand how these new drugs work and all types of patients, because there may be differences and how effective therapies might be from one population of patients to another. So creating equity through both availability of therapy and availability of clinical trials, to me, is really critical to advancing the field. And I think we have a long way to go on to achieve that. But certainly, efforts towards making these new drugs available to patients in underserved communities is going to be very important.
And to that effect, being able to lower the cost of care is certainly going to be very important, as well, because [the] more out-of-pocket expense associated with these drugs, the less likely it is that underserved, or disadvantaged, or poor patients will be able to access these drugs. So there's a lot of a lot of moving parts here, but I am concerned about potential inequity in care when it comes to treating very serious, aggressive diseases with complicated therapies that are much more difficult to administer in the community setting or that require a lot of patient expense. So these are major concerns that we have to deal with as a health care community for sure—not just for AML, but for all cancers.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More